Regulus Therapeutics Inc (NASDAQ:RGLS) shot up 10.3% during trading on Monday . The stock traded as high as $1.39 and last traded at $1.28. 514,508 shares traded hands during mid-day trading, an increase of 97% from the average session volume of 260,717 shares. The stock had previously closed at $1.16.
Several brokerages have commented on RGLS. ValuEngine lowered shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Wedbush restated a “hold” rating and issued a $2.00 price target on shares of Regulus Therapeutics in a research note on Tuesday, April 9th. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Friday, March 29th. Finally, Wells Fargo & Co dropped their price target on shares of Regulus Therapeutics from $6.00 to $1.50 and set a “market perform” rating on the stock in a research note on Tuesday, March 19th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $1.06.
The company has a market cap of $23.84 million, a P/E ratio of -0.23 and a beta of 2.26.
In related news, Director Pascale Witz acquired 29,630 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were acquired at an average price of $1.08 per share, for a total transaction of $32,000.40. Following the completion of the purchase, the director now directly owns 37,849 shares of the company’s stock, valued at $40,876.92. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Joseph P. Hagan acquired 33,194 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were bought at an average price of $1.08 per share, for a total transaction of $35,849.52. Following the purchase, the chief executive officer now directly owns 64,542 shares of the company’s stock, valued at $69,705.36. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 1,199,528 shares of company stock worth $1,295,490 and sold 68,107 shares worth $83,478. 5.40% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Wedbush Securities Inc. increased its stake in shares of Regulus Therapeutics by 32.8% during the first quarter. Wedbush Securities Inc. now owns 43,489 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 10,751 shares during the period. Jane Street Group LLC acquired a new position in shares of Regulus Therapeutics during the first quarter valued at approximately $64,000. Virtu Financial LLC acquired a new position in shares of Regulus Therapeutics during the first quarter valued at approximately $68,000. Finally, Renaissance Technologies LLC increased its stake in shares of Regulus Therapeutics by 72.2% during the first quarter. Renaissance Technologies LLC now owns 275,693 shares of the biopharmaceutical company’s stock valued at $281,000 after acquiring an additional 115,625 shares during the period. Institutional investors and hedge funds own 25.17% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Regulus Therapeutics (RGLS) Shares Up 10.3%” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2019/05/20/regulus-therapeutics-rgls-shares-up-10-3.html.
Regulus Therapeutics Company Profile (NASDAQ:RGLS)
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Featured Article: Institutional Investors
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.